Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Inclusion Criteria: * Malignant Disease * Chronic myleogenous leukemia in chronic or accelerated phase * Acute lymphoblastic leukemia (ALL) * First remission high-risk ALL (Ph+, t( 4-11) infants). * Second remission ALL, after a short first remission (\<36 mos from Dx). * 3rd or greater remission ALL. * Acute myelogenous leukemia (AML) * First remission high risk acute nonlymphoblastic (ANLL) (as defined by cytogenetics), if a matched sibling donor is available. * Initial partial remission AML (\<20% blasts in the bone marrow). * AML that is refractory to two cycles of induction therapy. * Second or greater remission AML * Myelodysplastic/Myeloproliferative Disease * Juvenile Myelomonocytic Leukemia (JMML) * Myelosplastic syndrome and/or pre-leukemia at any stage * Lymphoma * Relapsed lymphoma with residual disease that appears to be chemo-sensitive and non-bulky (\<5 cm at largest diameter) * Venous Access: Three lumens of central vascular access will be required for all patients entered on protocol due to the need for a dedicated line for continuous infusion cyclosporine. * Informed Consent: The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. * Patient organ function requirements: * Adequate renal function: Serum Creatinine \<\~1.5 x normal, or Creatinine clearance of 70 mL/min/1.73 mE2 or an equivalent GFR as determined by the institutional normal range * Adequate liver function: Total bilirubin \<1.5 x normal; and SGOT (AST) or SGPT (ALT) \<\~2.5 x normal * Adequate cardiac function: Shortening fraction of \>/=27% by echocardiogram * Adequate pulmonary function: FEV1/FVC \>/=60% by pulmonary function test; for children who are uncooperative, no evidence of dysnpea at rest, or exercise intolerance, and must have a pulse oximetry \>94% in room air * Performance status: Lansky for children \</= 16 years \>/= 60; Karnofsky status for those \> 16 years of age \>/= 70 * Effective Contraceptive Use: Women of childbearing potential and sexually active males should use effective contraception while on study. Exclusion Criteria: * Patients who are pregnant or lactating * Inability to find a suitable donor for the patient * Patient is HIV-positive * Patient has active Hepatitis B * Disease progression or relapse prior to HPC infusion